Novara Biotech reports quarterly revenue above the internal plan
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
Novara Biotech
Healthcare · Biotechnology
Updated UTC
$410,77
+5,46+%1,35
After hours$412,82+%0,50
| Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 31,67 Mr | 37,26 Mr | 41,96 Mr | 48,31 Mr | 53,67 Mr |
| Gross profit | 18,76 Mr | 21,53 Mr | 23,9 Mr | 26,46 Mr | 32,34 Mr |
| Operating income | 6,26 Mr | 7,62 Mr | 7,85 Mr | 9,58 Mr | 11,72 Mr |
| Net income | 4,88 Mr | 5,63 Mr | 6,17 Mr | 5,78 Mr | 7,65 Mr |
Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
The company approved a multi-year capital program intended to shorten lead times for its largest customers.
Sector Desk
A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.
Sector Desk
The board named an internal candidate with prior treasury and investor-relations experience to the role.
Sector Desk
The authorization covers a modest slice of the float and will be funded from operating cash flow.
Terminal Brief